Groups Dislike FDA-Recommended Trial Designs For Low-Glucose Suspend Systems

FDA’s recommended trial designs for early versions of “artificial pancreas” devices for type 1 diabetes patients are overly burdensome and will hinder development in the space, device makers and clinical societies say.